PENNSAUKEN, N.J. – Established in late 2019 by Otsuka America Pharmaceutical, Inc., the Sozosei Foundation has committed $500,000 in donations to five local charities in central New Jersey and Washington, D.C. areas to support those impacted by the Covid-19 Pandemic, including a $100,000 donation to the Food Bank of South Jersey, South Jersey’s largest and leading hunger-relief organization and a member of the Feeding America national network of leading food banks.
According to the Sozosei Foundation, the five leading charities selected focus on an array of critical services such as providing meals and housing services to at-risk community members including children and the elderly. In addition to the Food Bank of South Jersey, charities supported by the Sozosei Foundation include Meals on Wheels, Community Foodbank of New Jersey, Martha’s Table and Manna Food Center. These donations represent the first step for the Sozosei Foundation as part of a broader commitment to promote public awareness and education of healthcare issues, as well as to support charitable and qualified exempt organizations.
“The Sozosei Foundation will focus on supportive efforts in the areas of mental health and kidney diseases, disaster relief and local community outreach,” reports William H. Carson, MD, chairman, Sozosei Foundation, and chairman, Board of Directors, Otsuka Pharmaceutical Development & Commercialization, Inc. “We are excited that our initial donations will serve the communities where Otsuka has a major presence.”
Food Bank of South Jersey President and CEO Fred C. Wasiak states the Sozosei Foundation’s generous $100,000 donation will assist the leading food bank in meeting a more than 200 percent increase in demand for food at its food distributions throughout Burlington, Camden, Gloucester and Salem counties.
“We could not do what we do – feed South Jersey during this historic pandemic – without the support of leading organizations who recognize the essential role they play in the health, wellness and sustainability of the communities they serve,” Wasiak states. “We are so appreciative to the Sozosei Foundation and the entire Otsuka Pharmaceutial organization, for its willingness to help provide nutrition and wellness to thousands upon thousands of South Jersey residents struggling with the reality of hunger every day due to the economic impact of COVID-19 – we are incredibly grateful for the support of the Sozosei Foundation.”
“Unfortunately, the COVID-19 virus has already taken an enormous toll on too many families and our hearts go out to those who have been affected by this global pandemic,” reports Kabir Nath, board member, Sozosei Foundation and president & CEO, Otsuka North America Pharmaceutical Business. “We are seeing communities around the world come together to protect the most vulnerable and lessen the hardships on the millions of people worldwide who have been impacted the most. We feel privileged to contribute to each of these charitable organizations to help ensure people have access to basic necessities such as food and shelter during this time.”
Marking its 35th year in 2020, the Food Bank of South Jersey (FBSJ) is the leader in providing safe and nutritional food to people in need throughout South Jersey. FBSJ distributes food, provides nutrition education and cooking courses, and helps food-insecure families and seniors find sustainable ways to improve their lives. Throughout 2019, FBSJ distributed over 15 million pounds of food, more than 230,000 summer meals and over 17,500 senior food boxes, as well as serving 95 health and wellness programs to more than 11,700 residents. Providing community impact through local support, FBSJ ensures that local donations stay local. FBSJ is a member of Feeding America, our nation’s largest hunger-relief organization. To learn more, follow the Food Bank of South Jersey on Twitter @foodbankSJ or visit www.foodbanksj.org.
Established in late 2019 by Otsuka America Pharmaceutical, Inc., the Sozosei Foundation is a U.S.-based, private charitable foundation committed to the health and well-being of its communities, including improved patient diagnosis, treatment, care and quality of life, especially for those patients who are most in need.Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology and cardiology, using cutting-edge technology to address unmet healthcare needs. Otsuka’s most recently approved product in the U.S. is the first-ever treatment for autosomal dominant polycystic kidney disease, a genetic disorder in which fluid-filled cysts develop in the kidneys over time, often leading to kidney failure. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 11.7 billion in 2018. Learn more about Otsuka in the U.S. at www.otsuka-us.com or on Twitter @OtsukaUS.